Cargando…

Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients

OBJECTIVE: Urinary liver-type fatty acid-binding protein (u-LFABP) is a marker of tubulointerstitial inflammation and has been shown to be increased in patients with type 1 diabetes and is further increased in patients who progress to micro- and macroalbuminuria. Our aim was to evaluate u-LFABP as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nielsen, Stine Elkjaer, Sugaya, Takeshi, Hovind, Peter, Baba, Tsuneharu, Parving, Hans-Henrik, Rossing, Peter
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875447/ https://www.ncbi.nlm.nih.gov/pubmed/20185732 http://dx.doi.org/10.2337/dc09-2242

Ejemplares similares

Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes: An Inception Cohort Study
por: Hovind, Peter, et al.
Publicado: (2009)

Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition
por: Nielsen, Stine E., et al.
Publicado: (2009)

Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2011)

Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy
por: Zürbig, Petra, et al.
Publicado: (2012)

Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort
por: Ferreira, Isabel, et al.
Publicado: (2017)

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
por: Andersen, Sten, et al.
Publicado: (2010)

Urinary Liver-Type Fatty Acid–Binding Protein and Progression of Diabetic Nephropathy in Type 1 Diabetes
por: Panduru, Nicolae M., et al.
Publicado: (2013)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients
por: Kamijo-Ikemori, Atsuko, et al.
Publicado: (2011)

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy
por: Persson, Frederik, et al.
Publicado: (2010)

Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
por: Lund, Søren Søgaard, et al.
Publicado: (2008)

The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes
por: Dendooven, Amélie, et al.
Publicado: (2011)

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review
por: Persson, Frederik, et al.
Publicado: (2016)

Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria
por: Currie, Gemma E., et al.
Publicado: (2018)

Vitamin D Levels and Asymptomatic Coronary Artery Disease in Type 2 Diabetic Patients With Elevated Urinary Albumin Excretion Rate
por: Joergensen, Christel, et al.
Publicado: (2012)

Predictive Effects of Urinary Liver-Type Fatty Acid–Binding Protein for Deteriorating Renal Function and Incidence of Cardiovascular Disease in Type 2 Diabetic Patients Without Advanced Nephropathy
por: Araki, Shin-ichi, et al.
Publicado: (2013)

Vitamin D Levels and Mortality in Type 2 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2010)

Osteoprotegerin and Mortality in Type 2 Diabetic Patients
por: Reinhard, Henrik, et al.
Publicado: (2010)

Clinical significance of urinary liver-type fatty acid binding protein at various stages of nephropathy
por: Viswanathan, V., et al.
Publicado: (2015)

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
por: Gæde, Peter, et al.
Publicado: (2016)

Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs
por: TAKASHIMA, Satoshi, et al.
Publicado: (2021)

24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study
por: Theilade, Simone, et al.
Publicado: (2013)

Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
por: Oellgaard, Jens, et al.
Publicado: (2018)

Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis
por: Zhang, Li, et al.
Publicado: (2022)

Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients
por: Reinhard, Henrik, et al.
Publicado: (2012)

Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes
por: Mutter, Stefan, et al.
Publicado: (2021)

Renal expression and urinary excretion of liver‐type fatty acid‐binding protein in cats with renal disease
por: Katayama, Masaaki, et al.
Publicado: (2020)

Elevation of urinary liver-type fatty acid binding protein after cardiac catheterization related to cardiovascular events
por: Kamijo-Ikemori, Atsuko, et al.
Publicado: (2015)

Urinary adiponectin and progression of diabetic nephropathy in type 1 diabetes
por: Ha, Kyoung Hwa, et al.
Publicado: (2015)

NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients
por: Reinhard, Henrik, et al.
Publicado: (2012)

Urinary liver-type fatty acid-binding protein in two dogs with acquired Fanconi syndrome: A case report
por: Takashima, Satoshi, et al.
Publicado: (2022)

Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria
por: Reinhard, Henrik, et al.
Publicado: (2011)

Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats
por: Tanabe, Jun, et al.
Publicado: (2020)

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study
por: Frimodt-Møller, Marie, et al.
Publicado: (2018)

NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis
por: Reinhard, Henrik, et al.
Publicado: (2011)

Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy
por: Broedbaek, Kasper, et al.
Publicado: (2011)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
por: Persson, Frederik, et al.
Publicado: (2009)

Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study
por: Gæde, Peter, et al.
Publicado: (2019)

Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy
por: Winther, Signe Abitz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mcf23n567hlb186avb6gsjn5s4